SCHEMBL2825009

SCHEMBL2825009

O=C(O)c1ccc(NC(=O)c2cccc(NS(=O)(=O)c3ccc4ccccc4c3)c2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR27 Q9NS67 1/20 0.74
AKR1C3 P42330 1/20 0.70
KMT2A Q03164 6/20 0.69
MEN1 O00255 5/20 0.69
MAPT P10636 1/20 0.60
TP53 P04637 1/20 0.59
THRB P10828 1/20 0.59
ALDH1A1 P00352 2/20 0.58
LMNA P02545 1/20 0.58
GAA P10253 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
POLB P06746 1/20 0.56
CYP2C9 P11712 1/20 0.56
ATIC P31939 1/20 0.56
CYP2C19 P33261 1/20 0.56
HSD17B10 Q99714 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825370 0.88 KMT2A (0.79) GPR27KMT2AMEN1MAPTTHRB
SCHEMBL7311403 0.88 AKR1C3 (0.85) GPR27AKR1C3KMT2AMEN1MAPT
SCHEMBL24125071 0.86 GPR27 (1.00) GPR27KMT2AMEN1MAPTALDH1A1
SCHEMBL7782154 0.85 ALDH1A1 (0.77) GPR27AKR1C3KMT2AMEN1MAPT
SCHEMBL2824645 0.84 AR (0.67) GPR27AKR1C3KMT2AMEN1MAPT
SCHEMBL2826898 0.84 KMT2A (0.69) KMT2AMEN1MAPTTP53THRB
SCHEMBL2823113 0.83 TCF4 (0.67) GPR27KMT2AMEN1MAPTTP53
SCHEMBL27702845 0.83 KDM1A (0.65) GPR27AKR1C3KMT2AMEN1MAPT
SCHEMBL2828714 0.83 MEN1 (0.74) KMT2AMEN1MAPTTP53THRB
SCHEMBL2824710 0.83 THRB (0.81) KMT2AMEN1MAPTTHRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2012-09-13 US claimed
CN-101189210-B Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors HOFFMANN LA ROCHE 2012-06-06 CN claimed
US-20110319438-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2011-12-29 US claimed
US-20100144762-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD 2010-06-10 US claimed
EP-1891001-B1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS HOFFMANN LA ROCHE (CH) 2010-05-05 EP claimed
CN-101189210-A Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors HOFFMANN LA ROCHE (CH) 2008-05-28 CN claimed
EP-1891001-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. Hoffmann-Roche AG (CH) 2008-02-27 EP claimed
WO-2006131452-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-14 WO claimed
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 US claimed
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM WAVEBREAK INC (US) 2024-06-27 US disclosed
WO-2022212568-A9 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM 1BASE PHARMACEUTICALS, LLC (US) 2023-11-16 WO disclosed
WO-2022212568-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM 1BASE PHARMACEUTICALS, LLC (US) 2022-10-06 WO disclosed
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2012-09-13 US disclosed
CN-101189210-B Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors HOFFMANN LA ROCHE 2012-06-06 CN disclosed
US-7723538-B2 enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid HOFFMANN-LA ROCHE INC. (US) 2010-05-25 US disclosed
EP-1891001-B1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS HOFFMANN LA ROCHE (CH) 2010-05-05 EP disclosed
CN-101189210-A Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors HOFFMANN LA ROCHE (CH) 2008-05-28 CN disclosed
EP-1891001-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. Hoffmann-Roche AG (CH) 2008-02-27 EP disclosed
WO-2006131452-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-14 WO disclosed
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors CPT1A, CPT1B, CPT2 GPR27 2547/4885AKR1C3 446/4885KMT2A 1890/4885
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 GPR27 2547/4885AKR1C3 446/4885KMT2A 1890/4885
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM CPT2, PC, SREBF2 GPR27 3370/4885AKR1C3 2151/4885KMT2A 4386/4885
US-20100144762-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 GPR27 2547/4885AKR1C3 446/4885KMT2A 1890/4885
US-20110319438-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 GPR27 2547/4885AKR1C3 446/4885KMT2A 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.